Navigation Links
RoosterBio Inc. and Tissue Regeneration Therapeutics Inc. Announce Alliance Around Scale-up Manufacturing of Umbilical Cord Tissue Perivascular Cell Technology
Date:12/10/2018

Today, RoosterBio Inc. and Tissue Regeneration Therapeutics Inc. (TRT) announce a strategic alliance to advance their shared goal of accelerating the development of the Regenerative Medicine field. This alliance will be focused on applying RoosterBio’s unique scale-up bioprocess systems to TRT’s core technology around human umbilical cord perivascular cells (HUCPVCs). Together, it is anticipated that these technology platforms will establish a new level of perivascular stromal cell manufacturing productivity, driving commercially-relevant lot sizes in scalable production platforms, thus creating newfound efficiencies in Regenerative Medicine.

“Tissue Regeneration Therapeutics have established themselves as leaders in cord tissue perivascular cells, and we are excited to collaborate to help drive cell manufacturing productivity within their unique technology platform.” said Margot Connor, RoosterBio’s CEO. She adds, “We’ve experienced great collaboration with TRT over the last few years, and we look forward to deepening our relationship with them.”

John E. Davies, DSc, CEO of TRT states, “RoosterBio have established themselves as leaders in hMSC bioprocess systems, and we are enthusiastic to apply their scalable, cGMP production platforms to our patented umbilical cord perivascular cellular (TXP) technology. We believe that our TXP technology has unique advantages over other mesenchymal cell sources, and leveraging RoosterBio’s scalable manufacturing platforms will accelerate our therapeutic programs. Overall, this is a collaboration with far reaching implications in the fields of Regenerative Medicine and Cellular Therapy.”

About RoosterBio, Inc.:
RoosterBio, Inc. is a privately held stem cell tools and technology company focused on accelerating the development of a sustainable Regenerative Medicine industry, one customer at a time. RoosterBio’s products are high volume, affordable, and well-characterized adult hMSCs paired with highly engineered bioprocess media systems. RoosterBio has simplified and standardized how stem cells are purchased, expanded, and used in development, leading to marked time and costs savings for customers. RoosterBio’s innovative products are ushering in a new era of productivity and standardization into the field, accelerating the road to discovery in Regenerative Medicine. For more information on RoosterBio and adult stem cells, please visit http://www.roosterbio.com, follow on twitter (@RoosterBio), or read the blog “Democratizing Cell Technologies” (http://www.roosterbio.blogspot.com).

About Tissue Regeneration Therapeutics Inc.:
TRT is a Canadian Controlled Private Corporation (CCPC) with a focus on the commercial development of their patented Human Umbilical Cord PeriVascular Cell (HUCPVC) technology platforms that include culture expanded cells (TXP) and engineered cells (eTXP). The latter are designed for specific unmet needs, in addition to the constitutive advantages of TXP, by the engineered secretion of cytokines, growth factors or monoclonal antibodies for targeted therapies. TRT is the first company in the world to have issued and allowed patents in the USA, Europe and Australasia, for extraction of these unique cells from umbilical cord tissue, and their gene engineering. Additional information is available at http://www.verypowerfulbiology.com.

Read the full story at https://www.prweb.com/releases/roosterbio_inc_and_tissue_regeneration_therapeutics_inc_announce_alliance_around_scale_up_manufacturing_of_umbilical_cord_tissue_perivascular_cell_technology/prweb15976335.htm.


'/>"/>
Source: PRWeb
Copyright©2018 Vocus, Inc.
All rights reserved


Related biology news :

1. RoosterBio, Inc. Earns NIIMBL Nod with 2 Grant Awards for Regenerative Medicine Manufacturing
2. Scientist.com and ZenBio, Inc. Partner to Offer Researchers Online Access to Human Skin Tissue for Screening Cosmetics and Personal Care Products
3. Asymmetrex Proposes “Stemgene Therapy” to Emphasize the Importance of Tissue Stem Cells for Successful Gene Therapy
4. Improving imaging of cancerous tissues by reversing time
5. First comprehensive meshfree numerical simulation of skeletal muscle tissue achieved
6. UW-Madison team developing tissue chip to screen neurological toxins
7. NIH funds next phase of Tissue Chip for Drug Screening program
8. The mechanics of tissue growth
9. K-to-M histone mutations: How repressing the repressors may drive tissue-specific cancers
10. New technology may identify tiny strains in body tissues before injuries occur
11. Tissue regeneration using anti-inflammatory nanomolecules
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2020)... ... May 20, 2020 , ... Catalent, ... drugs, biologics, cell and gene therapies, and consumer health products, today announced that ... be presenting at the ISCT 2020 Paris Virtual conference, which takes place on ...
(Date:5/14/2020)... NEW CENTURY, Kan. (PRWEB) , ... May 13, ... ... the North American launch of Bonlacta™, its latest enzyme for the lactose-free dairy ... production of a wide range of lactose-free dairy products at competitive costs across ...
(Date:5/1/2020)... (PRWEB) , ... April 30, 2020 , ... ... company backed by Siemens Healthineers and several healthcare VC firms announces an official ... goal of CareDoctors.com is to enhance patient care experience by offering live video ...
Breaking Biology News(10 mins):
(Date:5/21/2020)... ... May 20, 2020 , ... ... Simon Prakash, who will serve as the company’s executive vice president of product ... when Exo is disrupting the medical imaging space, bringing more than 24 years ...
(Date:5/15/2020)... , ... May 14, 2020 , ... ... undergo multiple open heart surgeries before becoming adults. The reason: there ... To address this critical unmet need, the Department of Defense has awarded Draper, ...
(Date:5/15/2020)... ... May 15, 2020 , ... Sentien Biotechnologies, Inc., a clinical-stage biotechnology company developing ... Chairman. Mr. Ganz will continue to lead Sentien’s Board of Directors, a role ... CEO Brian Miller and Sentien’s management team. , Mr. Ganz has more ...
(Date:5/14/2020)... Calif. (PRWEB) , ... May 12, 2020 , ... ... science tools for translational research, is bringing together thousands of industry leaders, clinicians, ... scientific program highlights two plenary speakers, Carl June, MD, Director of the Center ...
Breaking Biology Technology: